grepcent public filings, reorganized for comparison

EMERSON ELECTRIC CO (EMR)

CIK: 0000032604. SIC: 3600 Electronic & Other Electrical Equipment (No Computer Equip). Latest 10-K as of: 2025-11-10.

SIC breadcrumb: Manufacturing > Electronic And Other Electrical Equipment And Components, Except Computer Equipment > SIC 3600 Electronic & Other Electrical Equipment (No Computer Equip)

SEC company page: https://www.sec.gov/edgar/browse/?CIK=32604. Latest filing source: 0000032604-25-000087.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-09-30 · filed 2025-11-10 · accession 0000032604-25-000087 · source: SEC companyfacts

Revenue
18,016,000,000 USD verified
Net income
2,293,000,000 USD verified
Assets
41,964,000,000 USD verified
Free cash flow
2,667,000,000 USD computed
Net margin
12.73% computed
Revenue YoY
+3.00% computed
ROE
11.31% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

EMR ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 36; per-ratio N printed.EMR ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 36; per-ratio N printed.RatioEMRPeer medianPercentileNNet margin12.7%4.4%72135Revenue growth3.0%10.2%29142FCF margin14.8%8.0%70138ROE11.3%5.4%61136ROA5.5%2.7%62143Liabilities / equity1.070.8161138Current ratio0.882.593144

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue18,016,000,000USD20252025-11-10
Net income2,293,000,000USD20252025-11-10
Assets41,964,000,000USD20252025-11-10

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2025-11-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000032604.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric2016201720182019202020212022202320242025
Revenue15,264,000,00017,408,000,00018,372,000,00016,785,000,00012,932,000,00013,804,000,00015,165,000,00017,492,000,00018,016,000,000
Net income1,635,000,0001,518,000,0002,203,000,0002,306,000,0001,965,000,0002,303,000,0003,231,000,00013,219,000,0001,968,000,0002,293,000,000
Gross profit6,262,000,0006,404,000,0007,432,000,0007,815,000,0007,009,000,0007,563,000,0006,306,000,0007,427,000,0008,885,000,0009,519,000,000
Diluted EPS2.522.353.463.713.243.825.4122.883.434.04
Operating cash flow2,881,000,0001,912,000,0002,892,000,0003,006,000,0003,083,000,0003,575,000,0002,922,000,000637,000,0003,332,000,0003,098,000,000
Capital expenditures447,000,000476,000,000617,000,000594,000,000538,000,000404,000,000299,000,000363,000,000419,000,000431,000,000
Dividends paid1,227,000,0001,239,000,0001,229,000,0001,209,000,0001,209,000,0001,210,000,0001,223,000,0001,198,000,0001,201,000,0001,192,000,000
Share buybacks601,000,000400,000,0001,000,000,0001,250,000,000942,000,000500,000,000500,000,0002,000,000,000435,000,0001,167,000,000
Assets21,732,000,00019,589,000,00020,390,000,00020,497,000,00022,882,000,00024,715,000,00035,672,000,00042,746,000,00044,246,000,00041,964,000,000
Stockholders' equity7,568,000,0008,718,000,0008,947,000,0008,233,000,0008,405,000,0009,883,000,00010,364,000,00020,689,000,00021,636,000,00020,282,000,000
Free cash flow2,434,000,0001,436,000,0002,275,000,0002,412,000,0002,545,000,0003,171,000,0002,623,000,000274,000,0002,913,000,0002,667,000,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric2016201720182019202020212022202320242025
Net margin9.94%12.66%12.55%11.71%17.81%23.41%87.17%11.25%12.73%
Return on equity21.60%17.41%24.62%28.01%23.38%23.30%31.18%63.89%9.10%11.31%
Return on assets7.52%7.75%10.80%11.25%8.59%9.32%9.06%30.92%4.45%5.46%
Liabilities / equity1.871.251.281.491.721.502.441.071.051.07
Current ratio1.241.641.071.191.521.351.092.751.770.88

Industry Peer Context

Each number-line places EMR against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

EMR Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 4.EMR Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 4.4 SIC peersMin 9.6%Median 12.8%Max 19.0%EMR 12.7%

ROE peer context

EMR ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 3.EMR ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 3.3 SIC peersMin 11.3%Median 43.7%Max 46.6%EMR 11.3%

ROA peer context

EMR ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 4.EMR ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 3600; peer count 4.4 SIC peersMin 5.5%Median 7.2%Max 13.0%EMR 5.5%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

EMR FY2025 free cash flow bridge from reported figures.EMR FY2025 free cash flow bridge from reported figures.EMR free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$2.0B$4.0B$3.1BOperating cash flow-$431.0MCapex$2.7BFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0000032604-25-000087; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0000032604-25-000087; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0000032604-25-000087; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

EMR revenue, last 5 periods. Source: SEC companyfacts FY2025.EMR revenue, last 5 periods. Source: SEC companyfacts FY2025.EMR RevenueLatest point: FY2025 = $18.0BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$10.0B$20.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

EMR net income, last 5 periods. Source: SEC companyfacts FY2025.EMR net income, last 5 periods. Source: SEC companyfacts FY2025.EMR Net incomeLatest point: FY2025 = $2.3BSource: SEC companyfacts FY2025.Fiscal yearNet income$0.0B$10.0B$20.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

EMR gross profit, last 5 periods. Source: SEC companyfacts FY2025.EMR gross profit, last 5 periods. Source: SEC companyfacts FY2025.EMR Gross profitLatest point: FY2025 = $9.5BSource: SEC companyfacts FY2025.Fiscal yearGross profit$0.0B$5.0B$10.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

EMR diluted eps, last 5 periods. Source: SEC companyfacts FY2025.EMR diluted eps, last 5 periods. Source: SEC companyfacts FY2025.EMR Diluted EPSLatest point: FY2025 = $4.04/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)$0.00/share$15.00/share$30.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

EMR operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.EMR operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.EMR Operating cash flowLatest point: FY2025 = $3.1BSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

EMR capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.EMR capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.EMR Capital expendituresLatest point: FY2025 = $431.0MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

EMR dividends paid, last 5 periods. Source: SEC companyfacts FY2025.EMR dividends paid, last 5 periods. Source: SEC companyfacts FY2025.EMR Dividends paidLatest point: FY2025 = $1.2BSource: SEC companyfacts FY2025.Fiscal yearDividends paid$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: PaymentsOfDividendsCommonStock. Source concepts: us-gaap:PaymentsOfDividendsCommonStock.

EMR share buybacks, last 5 periods. Source: SEC companyfacts FY2025.EMR share buybacks, last 5 periods. Source: SEC companyfacts FY2025.EMR Share buybacksLatest point: FY2025 = $1.2BSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

EMR assets, last 5 periods. Source: SEC companyfacts FY2025.EMR assets, last 5 periods. Source: SEC companyfacts FY2025.EMR AssetsLatest point: FY2025 = $42.0BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$25.0B$50.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: Assets. Source concepts: us-gaap:Assets.

EMR stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.EMR stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.EMR Stockholders' equityLatest point: FY2025 = $20.3BSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

EMR free cash flow, last 5 periods. Source: SEC companyfacts FY2025.EMR free cash flow, last 5 periods. Source: SEC companyfacts FY2025.EMR Free cash flowLatest point: FY2025 = $2.7BSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-09-30; accession 0000032604-25-000087; filed 2025-11-10. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

5 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-04. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000032604.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-06-301.54reported discrete quarter
2023-Q12022-12-313.97reported discrete quarter
2023-Q22023-03-311.38reported discrete quarter
2023-Q32023-06-3016.28reported discrete quarter
2023-Q42023-09-304,090,000,000744,000,000derived Q4 = FY annual - nine-month YTD
2024-Q12023-12-314,117,000,000142,000,0000.25reported discrete quarter
2024-Q22024-03-314,376,000,000501,000,0000.87reported discrete quarter
2024-Q32024-06-304,380,000,000329,000,0000.57reported discrete quarter
2024-Q42024-09-304,619,000,000996,000,000derived Q4 = FY annual - nine-month YTD
2025-Q12024-12-314,175,000,000585,000,0001.02reported discrete quarter
2025-Q22025-03-314,432,000,000485,000,0000.86reported discrete quarter
2025-Q32025-06-304,553,000,000586,000,0001.04reported discrete quarter
2025-Q42025-09-304,855,000,000636,000,000derived Q4 = FY annual - nine-month YTD
2026-Q12025-12-314,346,000,000605,000,0001.07reported discrete quarter
2026-Q22026-03-314,562,000,000618,000,000reported discrete quarter
2026-Q32026-06-304,873,000,000718,000,0001.28reported discrete quarter

Quarterly Charts

EMR quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR Quarterly RevenueLatest point: 2026-Q3 = $4.9BSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Revenue$0.0B$3.0B$6.0B2023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000032604-26-000043; filed 2026-08-04. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

EMR quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR Quarterly Net incomeLatest point: 2026-Q3 = $718.0MSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Net income$0.0B$500.0M$1.0B2023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000032604-26-000043; filed 2026-08-04. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

EMR quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.EMR Quarterly Diluted EPSLatest point: 2026-Q3 = $1.28/shareSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Diluted EPS (USD/share)$0.00/share$10.00/share$20.00/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000032604-26-000043; filed 2026-08-04. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read EMR's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read EMR's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0000032604-26-000043.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-04. Report date: 2026-06-30.

Items 2 and 3.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars are in millions, except per share amounts or where noted)

OVERVIEW

For the third quarter of fiscal 2026, net sales were $4.9 billion, up 7 percent compared with the prior year. Underlying sales, which exclude foreign currency translation, acquisitions and divestitures, were up 6 percent. Foreign currency translation had a 1 percent favorable impact.

Earnings from continuing operations attributable to common stockholders were $718, up 24 percent, and diluted earnings per share from continuing operations were $1.28, up 24 percent compared with $1.03 in the prior year. Adjusted diluted earnings per share from continuing operations were $1.71, up 13 percent compared with $1.52 in the prior year. Overall, results reflected sales growth and strong operating performance.

The table below presents the Company's diluted earnings per share from continuing operations on an adjusted basis to facilitate period-to-period comparisons and provide additional insight into the underlying, ongoing operating performance of the Company. Adjusted diluted earnings per share from continuing operations excludes intangibles amortization expense, restructuring and related costs, first year purchase accounting related items and transaction-related costs, discrete taxes and certain gains, losses or impairments.

Three Months Ended June 30,20252026
Diluted earnings from continuing operations per share$1.031.28
Amortization of intangibles0.370.35
Restructuring and related costs0.060.13
Acquisition/divestiture fees and related costs0.060.05
Discrete taxes0.01
IEEPA tariff refunds(0.11)
Adjusted diluted earnings from continuing operations per share$1.521.71

The table below summarizes the changes in adjusted diluted earnings per share from continuing operations. The items identified below are discussed throughout MD&A, see further discussion above and in the Business Segments and Financial Position sections below.

Three Months Ended
Adjusted diluted earnings from continuing operations per share - June 30, 2025$1.52
Operations0.19
Foreign currency0.03
Share count0.01
Stock compensation(0.03)
Other(0.01)
Adjusted diluted earnings from continuing operations per share - June 30, 2026$1.71

18

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30

Following is an analysis of the Company’s operating results for the third quarter ended June 30, 2026, compared with the third quarter ended June 30, 2025.

20252026Change
(dollars in millions, except per share amounts)
Net sales$4,5534,8737%
Gross profit$2,3932,65511%
Percent of sales52.6%54.5%1.9 pts
SG&A$1,2661,3436%
Percent of sales27.8%27.6%(0.2) pts
Other deductions, net$298311
Amortization of intangibles$219204
Restructuring costs$3787
Interest expense, net$9585
Earnings from continuing operations before income taxes$73491625%
Percent of sales16.1%18.8%2.7 pts
Earnings from continuing operations common stockholders$58071824%
Percent of sales12.7%14.7%2.0 pts
Net earnings common stockholders$58671823%
Diluted EPS - Earnings from continuing operations$1.031.2824%
Diluted EPS - Net earnings$1.041.2823%
Adjusted Diluted EPS - Earnings from continuing operations$1.521.7113%

Net sales for the third quarter of fiscal 2026 were $4.9 billion, up 7 percent compared with 2025. Software & Systems sales were up 11 percent, Intelligent Devices sales were up 6 percent, and Safety & Productivity sales were up 3 percent. Underlying sales were up 6 percent on 3 percent higher volume and 3 percent higher price. Foreign currency translation had a 1 percent favorable impact. Underlying sales were up 10 percent in the U.S. and up 4 percent internationally. The Americas was up 8 percent, Europe was down 1 percent, and Asia, Middle East & Africa was up 8 percent (China down 3 percent).

In February 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act ("IEEPA") does not authorize the imposition of tariffs. Subsequently, on April 20, 2026, U.S. Customs and Border Protection launched an administrative portal through which eligible importers could submit claims for refunds. During the three months ended June 30, 2026, the Company filed certain claims and received tariff refunds of $82 ($0.11 per share), and the benefit was recorded in Cost of sales. The timing and amount of any further tariff refunds remain uncertain, and, accordingly, no benefit was recognized as of June 30, 2026 for any additional potential refunds related to IEEPA tariffs previously paid.

Cost of sales for the third quarter of fiscal 2026 were $2,218, an increase of $58 compared with 2025, and gross margin of 54.5 percent increased 1.9 percentage points. Gross margin increased primarily due to the tariff refunds discussed above.

Selling, general and administrative (SG&A) expenses of $1,343 increased $77 and SG&A as a percent of sales was 27.6 percent, a decrease of 0.2 percentage points. SG&A as a percent of sales decreased due to leverage on higher sales and savings from cost reduction actions.

Other deductions, net were $311 for the third quarter of fiscal 2026, an increase of $13 compared with the prior year, due to an increase in restructuring costs, partially offset by lower amortization. See Note 7.

19

Pretax earnings from continuing operations of $916 increased $182, up 25 percent compared with the prior year, reflecting strong operating results as well as the tariff refunds discussed above. Earnings increased $51 in Software & Systems and $55 in Intelligent Devices, and decreased $10 in Safety and Productivity. See the Business Segments discussion that follows and Note 15.

Income taxes were $198 in the third quarter of fiscal 2026 and $154 in 2025, resulting in effective tax rates of 22 percent and 21 percent, respectively. In the current year, the One Big Beautiful Bill Act (the "OBBBA") increased the effective tax rate by approximately 1 percentage point due to lower tax deduction for foreign-derived intangible income from the change to domestic research and development in fiscal 2026. The Company expects the OBBBA to slightly benefit the effective tax rate beginning in fiscal 2027.

Earnings from continuing operations attributable to common stockholders were $718, up 24 percent, and diluted earnings per share from continuing operations were $1.28, up 24 percent compared with $1.03 in the prior year. Adjusted diluted earnings per share from continuing operations were $1.71 compared with $1.52 in the prior year, up 13 percent. Overall, the increase in earnings per share reflected strong operating results. See the analysis above of adjusted earnings per share for further details.

The table below, which shows results on an adjusted EBITA basis, is intended to supplement the Company's discussion of its results of operations herein. The Company defines adjusted EBITA as earnings from continuing operations excluding interest expense, net, income taxes, intangibles amortization expense, restructuring and related costs, first year purchase accounting related items and transaction-related costs, and certain gains, losses or impairments. Adjusted EBITA and adjusted EBITA margin are measures used by management and may be useful for investors to evaluate the Company's operational performance.

Three Months Ended June 30,20252026Change
Earnings from continuing operations before income taxes$73491625%
Percent of sales16.1%18.8%2.7 pts
Interest expense, net9585
Amortization of intangibles269253
Restructuring and related costs4199
Acquisition/divestiture fees and related costs4432
IEEPA tariff refunds(82)
Adjusted EBITA from continuing operations$1,1831,30310%
Percent of sales26.0%26.7%0.7 pts

20

Business Segments

Following is an analysis of operating results for the Company’s business segments for the third quarter ended June 30, 2026, compared with the third quarter ended June 30, 2025. The Company defines segment earnings as earnings before interest and taxes. See Note 15 for a discussion of the Company's business segments.

SOFTWARE & SYSTEMS

20252026ChangeFXAcq/DivU/L
Sales:
Control Systems & Software$1,1201,1997%%%7%
Test & Measurement36044523%%%23%
Total$1,4801,64411%%%11%
Earnings:
Control Systems & Software$2712855%
Test & Measurement(26)11144%
Total$24529621%
Margin16.6%18.0%1.4 pts
Amortization of intangibles:
Control Systems & Software$114100
Test & Measurement107108
Total$221208
Restructuring and related costs:
Control Systems & Software$86
Test & Measurement13
Total$819
Adjusted EBITA$47452310%
Adjusted EBITA Margin32.1%31.8%(0.3) pts

Software & Systems sales were $1,644 in the third quarter of 2026, an increase of $164, or 11 percent. Underlying sales were up 11 percent on 7 percent higher volume and 4 percent higher price. Underlying sales increased 13 percent in the Americas and 16 percent in Asia, Middle East & Africa (China up 14 percent), while Europe decreased 1 percent. Control Systems & Software sales increased 7 percent, reflecting strong demand in power. Sales for Test & Measurement increased $85, or 23 percent, reflecting strength in semiconductor and aerospace & defense. Earnings for Software & Systems were $296, an increase of $51, or 21 percent, while margin increased 1.4 percentage points to 18.0 percent, reflecting leverage on higher sales, lower intangibles amortization and savings from cost reduction actions. Adjusted EBITA margin was 31.8 percent, a decrease of 0.3 percentage points.

21

INTELLIGENT DEVICES

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0000032604-25-000087. The complete FY 2025 MD&A is published at /company/EMR/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high. Filing date: 2025-11-10. Report date: 2025-09-30.

ITEM 7 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Safe Harbor Statement

This Annual Report on Form 10-K contains various forward-looking statements and includes assumptions concerning Emerson's operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to risks and uncertainties. Emerson undertakes no obligation to update any such statements to reflect later developments. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Emerson provides the cautionary statements set forth under Item 1A - “Risk Factors,” which are hereby incorporated by reference and identify important economic, political and technological factors, among others, changes in which could cause the actual results or events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions.

Non-GAAP Financial Measures

To supplement the Company’s financial information presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP), management periodically uses certain “non-GAAP financial measures,” as such term is defined in Regulation G under SEC rules, to clarify and enhance understanding of past performance and prospects for the future. Generally, a non-GAAP financial measure is a numerical measure of a company’s operating performance, financial position or cash flows that excludes or includes amounts that are included in or excluded from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. For example, non-GAAP measures may exclude the impact of certain items such as acquisitions or divestitures, amortization of intangibles, restructuring costs, discrete taxes, gains, losses and impairments, or items outside of management’s control, such as foreign currency exchange rate fluctuations. Management believes that the following non-GAAP financial measures provide investors and analysts useful insight into the Company’s financial position and operating performance. Any non-GAAP measure provided should be viewed in addition to, and not as an alternative to, the most directly comparable measure determined in accordance with U.S. GAAP, as identified in italics below. Further, the calculation of these non-GAAP financial measures may differ from the calculation of similarly titled financial measures presented by other companies and therefore may not be comparable among companies.

Underlying sales, which exclude the impact of significant acquisitions, divestitures and fluctuations in foreign currency exchange rates during the periods presented, are provided to facilitate relevant period-to-period comparisons of sales growth by excluding those items that impact overall comparability (U.S. GAAP measure: net sales).

Operating profit (defined as net sales less cost of sales and selling, general and administrative expenses) and operating profit margin (defined as operating profit divided by net sales) are indicative of short-term operational performance and ongoing profitability. Management closely monitors operating profit and operating profit margin of each business to evaluate past performance and actions required to improve profitability. EBIT (defined as earnings before deductions for interest expense, net, related party interest income, and income taxes) and total segment EBIT, and EBIT margin (defined as EBIT divided by net sales) and total segment EBIT margin, are financial measures that exclude the impact of financing on the capital structure and income taxes. Adjusted EBITA and adjusted segment EBITA (defined as earnings excluding interest expense, net, related party interest income, income taxes, intangibles amortization expense, restructuring expense, first year purchase accounting related items and transaction fees, and certain gains, losses or impairments) and adjusted EBITA margin and adjusted segment EBITA margin (defined as adjusted EBITA divided by net sales) are measures used by management to evaluate the Company's operational performance, as they exclude the impact of acquisition-related investments and non-operational items. EBITDA (defined as EBIT excluding depreciation and amortization) and EBITDA margin (defined as EBITDA divided by net sales) are also used as measures of the Company's current operating performance, as they exclude the impact of capital and acquisition-related investments. Adjusted EBITDA (defined as EBITDA excluding restructuring expense, first year purchase accounting related items and transaction fees, and certain gains, losses or impairments) and adjusted EBITDA margin (defined as Adjusted EBITDA divided by net sales) are also used to exclude the impact of non-operational items. All of these are commonly used financial measures

16

utilized by management to evaluate performance (U.S. GAAP measures: pretax earnings or pretax profit margin, segment earnings or segment margin).

Adjusted earnings and earnings per share, which exclude certain gains and losses, impairments, restructuring costs, impacts of acquisitions or divestitures, amortization of intangibles, discrete taxes, or other items provide additional insight into the underlying, ongoing operating performance of the Company and facilitate period-to-period comparisons by excluding the earnings impact of these items. Management believes that presenting adjusted earnings and earnings per share excluding these items is more representative of the Company’s operational performance and may be more useful for investors (U.S. GAAP measures: earnings, earnings per share).

Free cash flow (operating cash flow less capital expenditures) and free cash flow as a percent of net sales are indicators of the Company’s cash generating capabilities, and dividends as a percent of free cash flow is an indicator of the Company's ability to support its dividend, after considering investments in capital assets which are necessary to maintain and enhance existing operations. The determination of operating cash flow adds back noncash depreciation expense to earnings and thereby does not reflect a charge for necessary capital expenditures. Management believes that free cash flow, free cash flow as a percent of net sales and dividends as a percent of free cash flow are useful to both management and investors as measures of the Company’s ability to generate cash and support its dividend (U.S. GAAP measures: operating cash flow, operating cash flow as a percent of net sales, dividends as a percent of operating cash flow).

17

FINANCIAL REVIEW

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for EMR

Indicators mapped to this company's SIC classification (industry 3600 Electronic & Other Electrical Equipment (No Computer Equip)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Inflation (CPI / PCE / PPI), US labor market, Growth & output, Money & trade, Government finances, Sector employment, Industrial orders & inventories, Trade & external.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/EMR.md · JSON record: /company/EMR.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt